Religa, D., Styczynska, M., Peplonska, B., Gabryelewicz, T., Pfeffer, A., Chodakowska, M., Luczywek, E., Wasiak, B., Stepien, K., Golebiowski, M., Winblad, B. and Barcikowska, M. (2003) Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer’s disease and mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 16, 64-70. doi:10.1159/000070677

has been cited by the following article:

• TITLE: Homocysteine and asymmetric dimethylarginine concentrations in the plasma of Alzheimer’s disease patients with varying degrees of dementia

  AUTHORS: Jolanta Dorszewska, Jolanta Florczak-Wyspiańska, Anna Oczkowska, Mateusz Dezor, Michał Prendecki, Wojciech Kozubski

  KEYWORDS: Homocysteine; ADMA; Dementia; Alzheimer’s Disease

  JOURNAL NAME: Advances in Alzheimer's Disease, Vol.2 No.1, March 11, 2013

  ABSTRACT: Alzheimer’s disease (AD) is accompanied by elevated levels of homocysteine (Hcy). Homocysteine may induce elevated concentration of asymmetric dimethylarginine (ADMA). Both Hcy and ADMA are the amino acids thought to represent risk factors of vascular diseases. Studies were conducted on the plasma levels of Hcy and methionine (Met), estimated by HPLC with electrochemical detection, as well as on levels of ADMA and arginine (Arg), estimated by HPLC with fluorescent detection, in the AD patients with benign through to severe dementia estimated by MMSE scale and in a control group. The studies disclosed elevated levels of Hcy and ADMA in AD (Hcy, p